• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Construction and sequence analysis of recombinant HCV-1b replicon by replacing NS5A region].

作者信息

Li Jingtao, Zhou Bin, Zhou Yuanping, Zeng Yanli, Li Wei, Wang Junjie, Zhang Jian, Zhang Hao, Liu Shuwen

机构信息

Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.

出版信息

Nan Fang Yi Ke Da Xue Xue Bao. 2012 Jan;32(1):46-9.

PMID:22366003
Abstract

OBJECTIVE

To construct the recombinant HCV-1b replicon by replacing NS5A region using serum samples from patients with chronic hepatitis C (CHC) in South China and explore the biological characteristics of NS5A protein in response to antiviral therapy.

METHODS

The on-off plasmid containing the cutting sites of the restriction endonucleases MIu I and Bcl I was designed based on the backbone of robust HCV 1b replicon. The full-length fragments of HCV NS5A were amplified from different CHC patients by RT-PCR and cloned into pMD-18 vector, followed by sequence analysis of amino acid mutation of ISDR, PKRBD, V3 and IRRDR within the NS5A region. If the amplicon obtained contained no MIu I or Bcl I cutting sites, the NS5A fragment was re-amplified using primers containing the cutting sites and inserted into the replicon for replacement.

RESULTS

The full-length fragments of NS5A were obtained successfully from CHC patients. The core region of ISDR-V3 of NS5A was replaced in the HCV replicon plasmid and showed correct sequences. The amino acid mutations of ISDR and PKRBD within NS5A were more frequent in patients with sustained viral response (SVR) than those without SVR. A high variability in the amino acid sequence was observed in both IRRDR and V3 regions.

CONCLUSION

The plug-in type recombinant HCV replicon for replacement of NS5A region in the virus from CHC patients has been successfully constructed, which provides a basis for further investigation of the biological characteristics of NS5A protein, the mechanisms of interferon-resistance, and antiviral therapy of difficult-to-treat CHC.

摘要

相似文献

1
[Construction and sequence analysis of recombinant HCV-1b replicon by replacing NS5A region].
Nan Fang Yi Ke Da Xue Xue Bao. 2012 Jan;32(1):46-9.
2
NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.NS5A(ISDR-V3) 区域遗传变异性与突尼斯 HCV-1b 株对联合干扰素/利巴韦林治疗反应的相关性。
J Med Virol. 2009 Dec;81(12):2021-8. doi: 10.1002/jmv.21641.
3
Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.丙型肝炎病毒 NS5A 和核心蛋白的序列异质性与聚乙二醇干扰素/利巴韦林联合治疗的病毒学应答。
Microbiol Immunol. 2011 Jun;55(6):418-26. doi: 10.1111/j.1348-0421.2011.00331.x.
4
Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.丙型肝炎病毒 2a 型和 2b 型 NS5A 区序列异质性与聚乙二醇干扰素/利巴韦林治疗的临床结局。
PLoS One. 2012;7(2):e30513. doi: 10.1371/journal.pone.0030513. Epub 2012 Feb 2.
5
Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.对 HIV 合并感染患者接受聚乙二醇干扰素和利巴韦林治疗反应相关的 HCV 基因 1a 型 5'UTR、E2-PePHD 和 NS5A-PKRBD 基因组区域的纵向分析。
Antiviral Res. 2012 Aug;95(2):72-81. doi: 10.1016/j.antiviral.2012.05.015. Epub 2012 Jun 7.
6
Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.丙型肝炎病毒1型E2-PePHD、NS5A-PKRBD、NS5A-ISDR和NS5A-V3的突变及其与聚乙二醇干扰素-利巴韦林治疗反应的关系。
J Virol. 2008 Jul;82(13):6644-53. doi: 10.1128/JVI.02231-07. Epub 2008 Apr 30.
7
Is investigation of hepatitis C virus NS5A gene heterogeneity a tool for predicting long-lasting response to interferon therapy in patients with HCV-1b chronic hepatitis?丙型肝炎病毒NS5A基因异质性的研究是否是预测HCV-1b型慢性肝炎患者对干扰素治疗长期反应的一种工具?
J Viral Hepat. 2002 Sep;9(5):360-9. doi: 10.1046/j.1365-2893.2002.00379.x.
8
Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.对两种或更多种治疗无应答的慢性丙型肝炎1型患者的丙型肝炎病毒NS5A区域突变及其与新治疗应答的关系
World J Gastroenterol. 2017 Jul 7;23(25):4538-4547. doi: 10.3748/wjg.v23.i25.4538.
9
Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity.欧洲丙型肝炎病毒1b型分离株NS5A蛋白的序列分析及其与干扰素敏感性的关系。
J Gen Virol. 1998 Jun;79 ( Pt 6):1373-81. doi: 10.1099/0022-1317-79-6-1373.
10
Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population?对丙型肝炎病毒NS5A的PKRBD进行测序能否预测澳大利亚人群联合治疗的疗效?
J Gastroenterol Hepatol. 2004 May;19(5):551-7. doi: 10.1111/j.1440-1746.2003.03319.x.